These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 31521192

  • 1. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.
    de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH.
    Arthritis Res Ther; 2019 Sep 14; 21(1):208. PubMed ID: 31521192
    [Abstract] [Full Text] [Related]

  • 2. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
    van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D.
    Ann Rheum Dis; 2019 May 14; 78(5):610-616. PubMed ID: 30808625
    [Abstract] [Full Text] [Related]

  • 3. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, Pimenta S, Pimentel-Santos FM, Gomes JL, Aguiar R, Pinto P, Videira T, Catita C, Santos H, Borges J, Sequeira G, Ribeiro C, Teixeira L, Ávila-Ribeiro P, Martins FM, Canhão H, McInnes IB, Ribeiro RM, Fonseca JE.
    Ann Rheum Dis; 2020 Apr 14; 79(4):490-498. PubMed ID: 32193187
    [Abstract] [Full Text] [Related]

  • 4. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
    Mulder MLM, Vriezekolk JE, den Broeder N, Mahler EAM, Helliwell PS, van den Hoogen FHJ, den Broeder AA, Wenink MH.
    Trials; 2020 Feb 10; 21(1):155. PubMed ID: 32041657
    [Abstract] [Full Text] [Related]

  • 5. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Xu W, Xu S, Wu Z, Hsia EC.
    Arthritis Care Res (Hoboken); 2013 Nov 10; 65(11):1732-42. PubMed ID: 23861303
    [Abstract] [Full Text] [Related]

  • 6. The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes.
    De Marco G, Helliwell P, McGonagle D, Emery P, Coates LC, Hensor EMA, Marzo-Ortega H.
    BMC Musculoskelet Disord; 2017 Jul 18; 18(1):303. PubMed ID: 28720139
    [Abstract] [Full Text] [Related]

  • 7. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, Kalstad S, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2014 Jan 18; 73(1):132-7. PubMed ID: 23291385
    [Abstract] [Full Text] [Related]

  • 8. TNFi-induced sustained clinical remission in peripheral spondyloarthritis patients cannot be maintained with a step-down strategy based on methotrexate.
    Carron P, De Craemer AS, Renson T, Colman R, Elewaut D, Van den Bosch F.
    Rheumatology (Oxford); 2021 Oct 02; 60(10):4880-4883. PubMed ID: 33471112
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
    Lindström U, Di Giuseppe D, Delcoigne B, Glintborg B, Möller B, Ciurea A, Pombo-Suarez M, Sanchez-Piedra C, Eklund K, Relas H, Gudbjornsson B, Love TJ, Jones GT, Codreanu C, Ionescu R, Nekvindova L, Závada J, Atas N, Yolbas S, Fagerli KM, Michelsen B, Rotar Ž, Tomšič M, Iannone F, Santos MJ, Avila-Ribeiro P, Ørnbjerg LM, Østergaard M, Jacobsson LT, Askling J, Nissen MJ.
    Ann Rheum Dis; 2021 Nov 02; 80(11):1410-1418. PubMed ID: 34083206
    [Abstract] [Full Text] [Related]

  • 10. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME, GO-FURTHER Investigators.
    Arthritis Care Res (Hoboken); 2015 Dec 02; 67(12):1627-36. PubMed ID: 25623393
    [Abstract] [Full Text] [Related]

  • 11. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C, FUTURE 2 study group.
    Arthritis Res Ther; 2018 Dec 07; 20(1):272. PubMed ID: 30526678
    [Abstract] [Full Text] [Related]

  • 12. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F, Zhang FC, Bao CD, Tao Y, Gu JR, Xu JH, Zhu P, Xu HJ, Zhang ZY, Zhao DB, Wu DH.
    Zhonghua Nei Ke Za Zhi; 2009 Nov 07; 48(11):916-21. PubMed ID: 20079321
    [Abstract] [Full Text] [Related]

  • 13. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.
    Alexeeva E, Horneff G, Dvoryakovskaya T, Denisova R, Nikishina I, Zholobova E, Malievskiy V, Santalova G, Stadler E, Balykova L, Spivakovskiy Y, Kriulin I, Alshevskaya A, Moskalev A.
    Pediatr Rheumatol Online J; 2021 Jan 06; 19(1):5. PubMed ID: 33407590
    [Abstract] [Full Text] [Related]

  • 14. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.
    Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.
    Arthritis Res Ther; 2018 Aug 09; 20(1):174. PubMed ID: 30092827
    [Abstract] [Full Text] [Related]

  • 15. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
    Mease PJ, Accortt NA, Rebello S, Etzel CJ, Harrison RW, Aras GA, Gharaibeh MMF, Greenberg JD, Collier DH.
    Rheumatol Int; 2019 Sep 09; 39(9):1547-1558. PubMed ID: 31321485
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov 09; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 17. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME, Deodhar A, Schwartzman S, Chakravarty SD, Hsia EC, Leu JH, Zhou Y, Lo KH, Kavanaugh A.
    Arthritis Res Ther; 2022 Mar 21; 24(1):73. PubMed ID: 35313978
    [Abstract] [Full Text] [Related]

  • 18. Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.
    Izumiyama T, Mori Y, Oizumi I, Hamada S, Kurishima H, Terui H, Omori-Shimada R, Yamasaki K, Itoi E.
    J Orthop Surg (Hong Kong); 2021 Mar 21; 29(2):23094990211012286. PubMed ID: 33938296
    [Abstract] [Full Text] [Related]

  • 19. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

  • 20. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.
    Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB.
    Arthritis Rheumatol; 2019 Jul 18; 71(7):1112-1124. PubMed ID: 30747501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.